Colon Cancer, Metastatic Colorectal Cancer, Pancreas Cancer, Rectum Cancer, Recurrent Colorectal Carcinoma
Conditions
Keywords
Fluorescence, Surgery, Cancer, SGM-101, Near Infrared, Immunophotodetection
Brief summary
This study evaluates the safety and performance of SGM-101, a Carcinoembryonic Antigen (CEA)-specific chimeric antibody conjugated with a NIR emitting fluorochrome, for the visualization of CEA-expressing cancers during surgery. SGM-101 is injected 2 to 4 days before surgery and visualized using an optimized camera system.
Detailed description
Surgery is the most important therapy for patients with cancer of the colon, rectum or pancreas. Complete resection, which is a crucial factor in the prognosis of a patient, is challenging as surgeons have to rely on visual appearance and palpation to discriminate between tumor and normal tissue. Carcinoembryonic antigen (CEA) is a tumor-specific marker that is highly expressed in a number of tumors of epithelial origin (such as colorectal carcinoma and pancreas carcinoma) while it is minimally expressed in normal adult tissues. The compound that will be studied in this research project is SGM-101, a CEA-specific chimeric antibody conjugated with a near-infrared (NIR) emitting moiety. The hypothesis is that, following preoperative iv administration of SGM-101 in patients with carcinoma of the colon, rectum or pancreas, SGM-101 will bind to CEA expressing cancer cells and these cells can then be visualized with a NIR fluorescence imaging system, thereby increasing the chance of radical resection.
Interventions
DRUGSGM-101
4 days before surgery, SGM-101 will be administered to the patient by intravenous injections.
Sponsors
Centre for Human Drug Research, Netherlands
Leiden University Medical Center
Erasmus Medical Center
Catharina Ziekenhuis Eindhoven
Surgimab
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged over 18 years old; * Patient should be scheduled and eligible for surgery because of a clinical diagnosis of cancer of the colon, rectum or cancer of the pancreas; * Both pancreatic and colorectal cancer patients: Circulating plasma CEA ≥ the upper limit of normal range (eg ≥ 3.0 ng / ml); * Patient suffering from recurrences and metastasis of colorectal cancer: Rising circulating plasma CEA * Patients should be capable and willing to give informed consent before study specific procedures.
Exclusion criteria
* Anticancer therapy (e.g. chemotherapy, radiotherapy (except for routine pre-operative radiotherapy for colorectal cancer), targeted therapy, concomitant systemic immune therapy, or any experimental therapy) within 4 weeks before inclusion; * History of a clinically significant allergy; * Circulating plasma concentration CEA ≥ 300 ng / ml; * Other malignancies either currently active or diagnosed in the last 5 years, except adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma; * Patients pregnant or breastfeeding (pregnancy should be ruled out by an assay of βhCG plasma within 4±1 weeks prior to administration of the conjugate), lack of effective contraception in male or female patients with reproductive potential; * Laboratory abnormalities defined as: Colorectal cancer patients only: * Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the or; * Total bilirubin above 2 times the Upper Limit Normal (ULN) or; Both pancreatic and colorectal cancer patients: * Serum creatinine above 1.5 times the ULN or; * Absolute neutrophils counts below 1.5 x 109/L or; * Platelet count below 100 x 109/L or; * Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males); * Known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG) or hepatitis C virus (HCV) antibody or patients with untreated serious infections; * Any condition that the investigator considers to be potentially jeopardizing the patients' wellbeing or the study objectives.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with treatment-related adverse events | up to 10 days after the surgery | An Adverse Event (AE) is any untoward medical occurrence in a subject who is participating in a clinical study performed. The adverse event does not necessarily have to follow the administration of a study drug, or to have a causal relationship with the study drug. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory or vital sign finding), symptom, or disease temporally associated with the study participation, whether or not it is related to the study drug. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tumor-to-background ratio (TBR) for fluorescence | day 4 | — |
| Serum SGM-101 concentrations | up to 1 month after surgery | Individual serum SGM-101 concentrations will be plotted versus time per individual using both a linear and log y-axis. Additionally, concentration versus time curves will be plotted per treatment group as a spaghetti plot. Concentrations will be summarized by treatment group. |
Countries
Netherlands
Outcome results
None listed